share_log

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330

Benzinga ·  12:02  · Ratings

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $360 to $330.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment